Form 4: Bausch + Lomb Director Sarah Kavanagh Acquires Shares

Director Sarah B. Kavanagh acquired 15,842 common shares of Bausch + Lomb Corporation through an annual restricted share unit grant.

Summary

• Director Sarah B. Kavanagh received an annual grant of 15,842 restricted share units (RSUs).
• The transaction occurred on May 26, 2026, at a valuation of $15.78 per share.
• Following this transaction, the director's total beneficial ownership increased to 69,541 common shares.
• The RSUs are granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing reflecting standard director compensation rather than a strategic shift or market-moving event.

Positives

• Director alignment with shareholder interests through increased equity ownership.
• Standard annual equity compensation grant indicates stable corporate governance practices.

Negatives

• None identified; this is a routine compensatory transaction.

Risks

• None identified; this is a routine compensatory transaction.

Future Outlook

The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are standard practice in the pharmaceutical and medical device industry to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for large-cap healthcare companies.
• The use of an Omnibus Incentive Plan for director compensation is common among peers such as Alcon or CooperCompanies.

Stakeholder Impact

• Positive alignment of director interests with those of common shareholders.

Next Steps

• Vesting of the RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Insider Trading, Form 4, Director Compensation, Equity Grant